Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments

Group 1 - Tenaya Therapeutics has signed a research deal with Alnylam Pharmaceuticals worth up to $1.13 billion to develop treatments for heart diseases [1] - The collaboration will focus on treatments targeting up to 15 genetic causes over a two-year research period [1] - Alnylam will be responsible for all further drug development and commercialization of any resulting medicines [1] Group 2 - Tenaya could receive up to $10 million in upfront payments and additional research funding from Alnylam [1] - The company may also be eligible for up to $1.13 billion in milestone payments if the drugs are successfully developed and approved [1] - Alnylam's major growth driver is Amvuttra, which treats transthyretin amyloid cardiomyopathy (ATTR-CM) and recorded sales of $2.31 billion in 2025 [1]